ConductScience.org, home

Paper950490

Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum.

Schiltz JR and 1 other. J Invest Dermatol, 1976. Cited by 231 papers, by iCite.

Cite this record

ConductScience Library. Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. Papers, record 950490. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/950490

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum.
PubMed
Journal
J Invest Dermatol
PubMed
Year
1976
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
231
iCite
Relative citation ratio, by iCite
8.3
iCite
Revised in PubMed
2019-07-23
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Schiltz JRJ R
2Michel BB

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AcantholysisMajor topic
Immunoglobulin GMajor topic
PemphigusMajor topic
SkinMajor topic
Skin DiseasesMajor topic
Acanthocytes
Autoantibodies
Autoradiography
Culture Techniques
Humans

Source PubMed

Download CSV of topics

Cited by46

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 231 citations.

PMIDTitleJournalYearIn PapersSource
37503332Blocking soluble Fas Ligand ameliorates pemphigus: PC111 efficacy in ex-vivo human pemphigus models.Front Immunol2023https://conductscience.org/library/papers/37503332PubMed
35720332Mechanisms Causing Acantholysis in Pemphigus-Lessons from Human Skin.Front Immunol2022https://conductscience.org/library/papers/35720332PubMed
35330080Marked to Die-Cell Death Mechanisms for Keratinocyte Acantholysis in Pemphigus Diseases.Life (Basel)2022https://conductscience.org/library/papers/35330080PubMed
31552014Serological Diagnosis of Autoimmune Bullous Skin Diseases.Front Immunol2019https://conductscience.org/library/papers/31552014PubMed
30155465The Evolving Story of Autoantibodies in Pemphigus Vulgaris: Development of the "Super Compensation Hypothesis".Front Med (Lausanne)2018https://conductscience.org/library/papers/30155465PubMed
25795143Desmosomes in acquired disease.Cell Tissue Res2015https://conductscience.org/library/papers/25795143PubMed
20978359Homologous regions of autoantibody heavy chain complementarity-determining region 3 (H-CDR3) in patients with pemphigus cause pathogenicity.J Clin Invest2010https://conductscience.org/library/papers/20978359PubMed
20964642Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris.Clin Exp Immunol2010https://conductscience.org/library/papers/20964642PubMed
20671975Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris.Dermatol Res Pract2010https://conductscience.org/library/papers/20671975PubMed
20585596Experimental human cell and tissue models of pemphigus.Dermatol Res Pract2010https://conductscience.org/library/papers/20585596PubMed
20467217Autoimmune and infectious skin diseases that target desmogleins.Proc Jpn Acad Ser B Phys Biol Sci2010https://conductscience.org/library/papers/20467217PubMed
20178468Update on the cloning of monoclonal anti-desmoglein antibodies from human pemphigus patients: implications for targeted therapy.Vet Dermatol2009https://conductscience.org/library/papers/20178468PubMed
18386043The desmosome and pemphigus.Histochem Cell Biol2008https://conductscience.org/library/papers/18386043PubMed
17130286Inhibition of Rho A activity causes pemphigus skin blistering.J Cell Biol2006https://conductscience.org/library/papers/17130286PubMed
16297153Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris.Clin Exp Immunol2005https://conductscience.org/library/papers/16297153PubMed
11120754Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions.J Clin Invest2000https://conductscience.org/library/papers/11120754PubMed
10712434Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus.J Clin Invest2000https://conductscience.org/library/papers/10712434PubMed
9710446Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice.J Clin Invest1998https://conductscience.org/library/papers/9710446PubMed
8931866Proteinase inhibitors and pemphigus vulgaris. An in vitro and in vivo study.Arch Dermatol Res1996https://conductscience.org/library/papers/8931866PubMed
8486729Nomenclature of the desmosomal cadherins.J Cell Biol1993https://conductscience.org/library/papers/8486729PubMed

See all 46 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/950490

GET https://conductscience.org/api/papers/v1/950490/cited_by?page=2